Robert Goldman

Bob is a Senior Advisor at Valaria Technical Consultants (VTC), LLC, where he provides consulting on technology development/funding, drug discovery, and pre-clinical and clinical product development for therapeutics and diagnostics to prevent, treat, and mitigate infectious and other diseases. Bob has over 20 years of infectious disease research, product development, and scientific administration experience. He obtained his Ph. D. in Microbiology from the University of California, Los Angeles, and continued postdoctoral studies at the University of Massachusetts Medical Center, Worchester, MA, and the National Institutes of Health (NIH) in Bethesda, MD. Bob was awarded the prestigious Leverhulme Fellowship to teach and conduct research at Trinity College, Dublin, Ireland. His career includes 18 years with Abbott Laboratories, two years with Incara Research Laboratories and 14 years with the NIH. At the NIH Bob served and Program/Project Officer managing anti-infective grants and contracts, and as a member of the NIH project teams for Rapid Access to Intervention Development and Molecular Libraries Screening Networks. He served as Project Officer for TB Drug Discovery and Development Contracts covering discovery, high throughput screening,in vivo testing and product development support. These efforts led to discovery of in vitro and in vivo active compounds support for clinical development of Situro (FDA approved), preclinical support for CPZEN-45, and a successful high-throughput screening campaign leading to discovery of small molecules targeting MmpL3, DprE1 and Pks13 Bob currently serves as a member of the Scientific Advisory Committee for the Lilly TB Drug Discovery Initiative. He was also founding Editor and Editor-in-Chief of Infectious Disorders-Drug Targets (2000 to 2007 Bentham Science Publishers) and served as Co-editor and Editor for special topics issues on Tuberculosis Drug Discovery and Development, and HIV/AIDS Associated Malignancies and New Therapies. He has 79 peer-reviewed, 18 invited review publications, and two patents on Candida acid protease inhibitors and Methods for assaying transglycosylase reactions, and for identifying inhibitors. Bob has obtained over $30 M in government funding working with clients as a private consultant.